Abstract
This study aimed to investigate whether the miR-198 expression level is related to clinicopathological factors and prognosis of esophageal cancer. MicroRNA was extracted from esophageal cancer patients who underwent surgery for assessment using the Taqman@ MicroRNA assay. The correlation between miR-198 expression and clinicopathological features was analyzed, and the significance of miR-198 as a prognostic factor and its relationship with survival was determined. MicroRNA-198 (miR-198) expression was higher in patients with poor prognosis than those with good prognosis (P < 0.05). Kaplan-Meier analysis results showed that the miR-198 expression level had a significant correlation with survival time (P = 0.030) and that patients with a higher expression of miR-198 had a shorter survival time. Cox multi-factor model analysis showed that patient prognosis (P = 0.014), tumor length (P = 0.040) and expression (P = 0.012), and survival time had a significant correlation; the corresponding risks were 7.268, 1.246, and 3.524, respectively. miR- 198 overexpression is involved in the poor prognosis of esophageal cancer and can be used as a biomarker for selection of cases requiring especial attention.
Highlights
Esophageal cancer (EC) is one of the eight most common tumors in the world
This study aimed to investigate whether the miR-198 expression level is related to clinicopathological factors and prognosis of esophageal cancer
Cox multi-factor model analysis showed that patient prognosis (P = 0.014), tumor length (P = 0.040) and expression (P = 0.012), and survival time had a significant correlation; the corresponding risks were 7.268, 1.246, and 3.524, respectively
Summary
Esophageal cancer (EC) is one of the eight most common tumors in the world. The incidence of EC is high in China, and mortality due to EC is high in the world, with an average case fatality rate of 15.59/10,0000 (Parkin et al, 2005). The disease is usually determined by clinical diagnosis in the middle-late period, and the fiveyear survival rate is lower than 20%. Its clinical treatments mainly include surgery, radiation therapy, and chemotherapy. The disease has a low survival rate. To determine a specific biomarker at the gene level and establish effective prevention, obtaining an early diagnosis method has become one of the research focuses in the field of tumor and EC prevention (Matsushima et al, 2010)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
